This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 treatment regimens of oral GED-0301 versus placebo in subjects with active CD (defined by a CDAI score ? 220 and ? 450 and a total SES-CD ? 6 at screening, or the ileum segmental SES-CD ? 4 at screening).